Overview
Location
Switzerland, Vaud, Lausanne
Employees
1-10
Founders name
Margaux Duchamp
Investors 2
| Date | Name | Website |
| Sign up to see | Sign up to see | Sign up to see |
| VentureLab | venturelab.swiss |
Persons 1
| Date | First Name | Last Name | Title | |||
| Sign up to see | Sign up to see | Sign up to see | Sign up to see | Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 11
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| May 4, 2022 | Swiss entrepreneurs secure a spot in the Forbes 30 Under 30 Europe list | |
| Apr 1, 2022 | Venture Leaders Medtech 2022: 10 innovative startups will advance their global growth in Boston | |
| Dec 16, 2021 | IMD 37 Startup Competition 2022 Winners announced | |
| Oct 15, 2021 | Margaux Duchamp wins Lopez-Loreta Foundation Prize 2021 | ArcoScreen has developed a new cell membrane receptor screening platform based on a microfluidic system and focusing on G Protein Coupled Receptors (GPCRs). This novel and unique patented assay embedded in a microfluidic chip, called SynScr... |
| Aug 26, 2021 | ArcoScreen wins CHF 150,000 to revolutionize drug discovery | G-Protein-Coupled Receptors (GPCRs) represent 35% of all approved modern drug targets globally and 25% of the 200 most profitable drugs sold in the USA. These membrane proteins are the most successful drug targets to treat diseases like can... |
| Jan 28, 2021 | Musy Award goes to two EPFL Female Entrepreneurs | |
| Jan 28, 2021 | Musy Award goes to two EPFL Female Entrepreneurs | The first winner is Clara Moldovan, CEO and founder of Lausanne based Swistor. Battery life has become a significant selection criterion when purchasing a mobile device; however, the slow charging systems and shorter lifespan of the batteri... |
| Jan 21, 2021 | CHF 40,000 for startups revolutionizing G protein coupled receptors screening, developing tracers for early detection of neurological diseases, and precision diagnostics for cancer treatment | ArcoScreen: revolutionizing G protein coupled receptors screening G protein coupled receptors (GPCRs) are the most successful drug targets to treat diseases like cancer, Parkinson’s or Alzheimer’s. Current assays to find new drugs are limit... |
| Aug 24, 2020 | Startups Revolutionizing G Protein Coupled Receptors Screening, Developing Next-Generation Microscopes Slides, Oral Microbiome Therapies to Treat Chronic Kidney Disease, and Digitizing Humans Each win CHF 10,000 | ArcoScreen: revolutionizing G protein coupled receptors screening G protein coupled receptors (GPCRs) are the most successful drug targets to treat diseases like cancer, Parkinson’s or Alzheimer’s. Current assays to find new drugs are limit... |
Show more
Reviews 0
FAQ about ArcoScreen
Who has invested in ArcoScreen?
Parsers VC lists 2 investors of ArcoScreen, among them VentureLab.
What has the press written about ArcoScreen?
Parsers VC has collected 11 articles mentioning ArcoScreen, among them “Swiss entrepreneurs secure a spot in the Forbes 30 Under 30 Europe list” (May 4, 2022) and “Venture Leaders Medtech 2022: 10 innovative startups will advance their global growth in Boston” (Apr 1, 2022).
Is ArcoScreen still active?
Yes, ArcoScreen is active; its latest activity on Parsers VC dates from Oct 12, 2022.